Skip to main content
. 2017 Feb 10;8(3):388–394. doi: 10.7150/jca.16804

Figure 2.

Figure 2

Overall survival (OS) of all patients treated with and without bevacizumab (a); OS of patients grouped by primary tumor location in chemotherapy (CT) group (b); OS of patients grouped by primary tumor location in chemotherapy plus bevacizumab (CT + B) group (c); OS of patients in CT group and CT + B in patients with right-side colon cancer (d), left-side colon cancer (e) and rectal cancer (f).